Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Reviewed by TrialFinderData Editorial Team · Updated

8 clinical trials · 8 recruiting · OTHER

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins has 8 clinical trials registered on ClinicalTrials.gov, with 8 actively recruiting participants. The trials listed below cover 14 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\'s Trial Portfolio

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

8 of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's 8 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's research footprint spans Metastatic Castration-resistant Prostate Cancer (1 trials), Acute Leukemia (1), and acute-lymphoblastic-lymphoma (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Not Applicable is the largest single phase in Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's portfolio at 50% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

RECRUITINGPhase 2NCT06922318

The COSMYC Trial (COmbined Suppression of MYC)

This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 501 location
Metastatic Castration-resistant Prostate Cancer
RECRUITINGNCT06803745

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in...

This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 1601 location
Acute LeukemiaAcute Lymphoblastic Lymphoma
RECRUITINGNCT07512154

Precision Radiotherapy Enabled by Molecular MRI

This is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 201 location
Brain Cancer
RECRUITINGPhase 1NCT04248569

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar...

The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 561 location
Fibrolamellar Hepatocellular Carcinoma (FLC)
RECRUITINGNCT06138067

Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients

The goal of this clinical trial is to test the utility of patient navigation by comparing high intensity patient navigation to low intensity navigation approaches to improving...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 902 locations
Prostate CancerKidney Cancer
RECRUITINGNCT02993900

Image-Guided Gynecologic Brachytherapy

This research is being done to evaluate multimodality imaging, including magnetic resonance imaging-guided therapy (MRT), as a possible treatment for gynecologic cancers. The...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 541 location
Cervical CancerUterine CancerVaginal Cancer+2
RECRUITINGPhase 1NCT04892303

Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer

The goal of this study is to evaluate combined radioactive iodine (RAI, 131-I) and external beam radiotherapy (XRT) to optimize the radiation dose delivered to treat well...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 481 location
Recurrent Thyroid Cancer
RECRUITINGPhase 1NCT06564623

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract...

The purpose of this study is to evaluate the safety and the immune response of personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax) in combination with durvalumab...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 251 location
Biliary Tract Cancers

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have on ClinicalTrials.gov?

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins has 8 clinical trials registered on the federal ClinicalTrials.gov registry, of which 8 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins study?

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's registered trials cover 14 conditions on ClinicalTrials.gov, led by Metastatic Castration-resistant Prostate Cancer (1 trial), Acute Leukemia (1 trial), acute-lymphoblastic-lymphoma (1 trial), Brain Cancer (1 trial), fibrolamellar-hepatocellular-carcinoma-flc (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 8 trials tracked for Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.